231 related articles for article (PubMed ID: 16191482)
41. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of primary and secondary resistant mutations to antiretroviral drug in a population of Puerto Rican infected with HIV.
Torres Rivera B; Vallés V; Ríos Olivares E
P R Health Sci J; 2002 Dec; 21(4):329-36. PubMed ID: 12572241
[TBL] [Abstract][Full Text] [Related]
43. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
44. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
[TBL] [Abstract][Full Text] [Related]
45. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
46. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
[TBL] [Abstract][Full Text] [Related]
47. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
48. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
49. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.
Arnedo-Valero M; Garcia F; Gil C; Guila T; Fumero E; Castro P; Blanco JL; Miró JM; Pumarola T; Gatell JM
Clin Infect Dis; 2005 Sep; 41(6):883-90. PubMed ID: 16107990
[TBL] [Abstract][Full Text] [Related]
50. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
51. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
Nadembega WM; Giannella S; Simpore J; Ceccherini-Silberstein F; Pietra V; Bertoli A; Pignatelli S; Bellocchi MC; Nikiema JB; Cappelli G; Bere A; Colizzi V; Perno CP; Musumeci S
J Med Virol; 2006 Nov; 78(11):1385-91. PubMed ID: 16998878
[TBL] [Abstract][Full Text] [Related]
52. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
[TBL] [Abstract][Full Text] [Related]
53. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
54. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
55. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
[TBL] [Abstract][Full Text] [Related]
56. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
57. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Chappell BJ; Margot NA; Miller MD
AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698
[TBL] [Abstract][Full Text] [Related]
58. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
59. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
